Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 121Neoplasms, Plasma Cell 36Neoplasms 14Carcinoma, Hepatocellular 13Recurrence 12Brain Neoplasms 12Prostatic Neoplasms 11Melanoma 11Central Nervous System Neoplasms 11Glioblastoma 10Leukemia 9Carcinoma, Non-Small-Cell Lung 9Leukemia, Lymphocytic, Chronic, B-Cell 8Gliosarcoma 8Waldenstrom Macroglobulinemia 7Sarcoma 7Lung Neoplasms 7Glioma 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Liver Neoplasms 6Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma 5Kidney Neoplasms 5Immunoglobulin Light-chain Amyloidosis 5Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, Follicular 4

Interventions

fludarabine phosphate 29Etoposide 26pegaspargase 24Peripheral Blood Stem Cell Transplantation 23Cyclophosphamide 23Whole-Body Irradiation 21Mycophenolic Acid 21Gemcitabine 19Busulfan 19Methotrexate 16Dexamethasone 16Tacrolimus 15Cyclosporine 14Antilymphocyte Serum 13Radiotherapy 12Oxaliplatin 10Rituximab 9Melphalan 8Asparaginase 8Doxorubicin 7Bortezomib 7spartalizumab 6Vorinostat 6Lenalidomide 6Flow Cytometry 6tislelizumab 5Vincristine 5Therapeutics 5Methylprednisolone 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Extranodal NK-T-Cell × Thalidomide × Clear all
NCT02085655 2021-03-15

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Sun Yat-sen University

Phase 3 Unknown
264 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡